ABT


Abbott Jumps 22% On Emergency Use Nod For Credit Card Size Covid-19 Test

Abbott Laboratories spiked 22% in Wednesday’s extended market session after announcing that the US Food and Drug Administration (FDA) issued Emergency Use Authorization (EUA) …

Abbott Labs, Edwards Lifesciences Settle Heart Device Patent Disputes

Abbott Laboratories (ABT) announced on Monday that it has reached an agreement with Edwards Lifesciences Corp. (EW) to settle all outstanding patent disputes related …

Abbot Laboratories: COVID-19 Tests Will Drive Further Growth, 5-Star Analyst Raises Price Target

Unlike other smaller healthcare companies, powerhouse Abbott Laboratories (ABT) hardly needed a global pandemic to raise awareness. The healthcare giant was performing well …

Abbot Labs Rolls Out Coronavirus Antibody Test, Seeks to Produce 20 Million Tests by June

Abbott Laboratories (ABT) said it is rolling out a laboratory-based blood test which can detect antibodies designed to identify whether someone has had …

Will These 3 Coronavirus Stocks Lead the Market to Recovery?

Almost three months have passed since COVID-19 began its spread beyond China’s borders, and the market remains in free fall. Capping off another volatile week, stocks fell on Friday April 3 in response …

May 2015 Dividend Aristocrats Spreadsheet List: KO, XOM, WMT, and More!

There are currently 53 Dividend Aristocrats.  A stock must have increased its dividend payments for 25 or more consecutive years to be a …

Dividend Aristocrats & The Sharpe Ratio: Part 2 of 4

In Part 1, the efficacy of investing in the Dividend Aristocrats Index was discussed. In addition, the current list of Dividend Aristocrats sorted …

Abbott Labs Well Positioned For Success In 2015

Abbott Laboratories (NYSE:ABT) Abbott Laboratories is a leading pharmaceutical medical devices and diagnostics company with contribution from four major business segments. These segments …

William Blair Assigns Outperform On Abbott Laboratories Shares

In a research report issued today, William Blair analyst Ben Andrew assigned an Outperform rating on Abbott Laboratories (NYSE:ABT). No price target was …

William Blair Reaffirms Outperform On Abbot Following The Sale Of Generic Drugs Business

In a research note issued yesterday, William Blair analyst Ben Andrew reaffirmed an Outperform rating on Abbott Laboratories (ABT). The report followsyesterday’s news that Abbott will …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts